We are live on ! Find out more
DCOY

Decoy Therapeutics
DCOY

3 hedge funds and large institutions have $62.1K invested in Decoy Therapeutics in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.02% more ownership

Funds ownership: 0% → 0.02% (+0.02%)

39% less capital invested

Capital invested by funds: $102K → $62.1K (-$39.8K)

57% less funds holding

Funds holding: 7 → 3 (-4)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
3
Holders Change
-4
Holders Change %
-57.14%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$44.9K
2
TRCT
Tower Research Capital (TRC)
New York
+$7.93K
3
UBS Group
UBS Group
Switzerland
+$661

Top Sellers

Rank Fund Capital Flow
1
HKAM
Horizon Kinetics Asset Management
New York
-$16.4K
2
Renaissance Technologies
Renaissance Technologies
New York
-$15K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$13.1K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$7.7K
5
Osaic Holdings
Osaic Holdings
Arizona
-$661

DCOY Hedge Fund Activity: Q2 2024 in Review

3 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q2 2024, worth a combined $62.1K — down 39% from $102K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of DCOY and 1 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was Armistice Capital, adding an estimated $44.9K. The largest seller was Horizon Kinetics Asset Management, exiting entirely with an estimated $16.4K sold.

  • 3 institutional investors held Decoy Therapeutics (DCOY) as of Q2 2024, down from 7 in Q1 2024.
  • Funds reported $62.1K of Decoy Therapeutics stock for Q2 2024, down 39% quarter-over-quarter.
  • 1 fund opened new Decoy Therapeutics positions in Q2 2024 and 5 closed out, a net change of -4 holders.
  • The largest Decoy Therapeutics buyer in Q2 2024 was Armistice Capital, an estimated $44.9K added.
  • The largest Decoy Therapeutics seller in Q2 2024 was Horizon Kinetics Asset Management, an estimated $16.4K sold.

Based on aggregated 13F filings for Q2 2024.